KESIMPTA PEN (ofatumumab)
ANTINEOPLASTIC MONOCLONAL ANTIBODIES · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
Novartis Pharmaceuticals
Drug class
Multiple Sclerosis Agent - CD20 Specific Monoclonal Antibody
The classification "Multiple Sclerosis Agent - CD20 Specific Monoclonal Antibody" is a compendial and formulary-standard drug class (such as within the First Databank Enhanced Therapeutic Classification System) encompassing disease-modifying therapies designed to treat multiple sclerosis. Read more about Multiple Sclerosis Agent - CD20 Specific Monoclonal Antibody
5 drugs in this class 4 manufacturers
Drugs in Multiple Sclerosis Agent - CD20 Specific Monoclonal Antibody
OCREVUS (ocrelizumab)
MONOCLONAL ANTIBODY IMMUNOSUPPRESSIVES · RELAPSING REMITTING MULTIPLE SCLEROSIS ·+3
GENENTECH
KESIMPTA PEN (ofatumumab)
ANTINEOPLASTIC MONOCLONAL ANTIBODIES · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
Novartis Pharmaceuticals
BRIUMVI (ublituximab-xiiy)
MONOCLONAL ANTIBODY IMMUNOSUPPRESSIVES · RELAPSING FORM OF MULTIPLE SCLEROSIS
TG THERAPEUTICS
OCREVUS ZUNOVO (ocrelizumab-hyaluronidase-ocsq)
MONOCLONAL ANTIBODY IMMUNOSUPPRESSIVES · RELAPSING REMITTING MULTIPLE SCLEROSIS ·+3
GENENTECH
Filter & compare in the drug finder →
Opens the drug finder with Multiple Sclerosis Agent - CD20 Specific Monoclonal Antibody preselected. Add indication or manufacturer filters there.
The classification "Multiple Sclerosis Agent - CD20 Specific Monoclonal Antibody" is a compendial and formulary-standard drug class (such as within the First Databank Enhanced Therapeutic Classification System) encompassing disease-modifying therapies designed to treat multiple sclerosis.
These agents selectively bind to the CD20 cell-surface antigen expressed on pre-B and mature B lymphocytes, mediating targeted cell depletion via mechanisms including antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
By reducing circulating B cells involved in autoimmune neuroinflammation, these therapies suppress relapses and slow disability accumulation in relapsing forms of multiple sclerosis and primary progressive multiple sclerosis.
-
iehp.org
The classification "Multiple Sclerosis Agent - CD20 Specific Monoclonal Antibody" is a compendial and formulary-standard drug class (such as within the First Databank Enhanced Therapeutic Classification System) encompassing disease-modifying therapies designed to treat multiple sclerosis
-
berkeley.edu
The classification "Multiple Sclerosis Agent - CD20 Specific Monoclonal Antibody" is a compendial and formulary-standard drug class (such as within the First Databank Enhanced Therapeutic Classification System) encompassing disease-modifying therapies designed to treat multiple sclerosis
-
formularynavigator.com
By reducing circulating B cells involved in autoimmune neuroinflammation, these therapies suppress relapses and slow disability accumulation in relapsing forms of multiple sclerosis and primary progressive multiple sclerosis
-
iehp.org
By reducing circulating B cells involved in autoimmune neuroinflammation, these therapies suppress relapses and slow disability accumulation in relapsing forms of multiple sclerosis and primary progressive multiple sclerosis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.